NASDAQ:DRTS

Alpha Tau Medical (DRTS) Stock Forecast, Price & News

$3.47

-0.12 (-3.34%)

(As of 11:31 AM ET)

Compare

Today's Range: $3.47
▼
$3.60
50-Day Range: $2.95
▼
$3.97
52-Week Range: $2.75
▼
$5.95

Volume: 15,825 shs
Average Volume: 62,290 shs
Market Capitalization: $240.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.67

Alpha Tau Medical MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 322.7% Upside
$14.67 Price Target
Short Interest: Healthy
0.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.43
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.50) to ($0.61) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

280th out of 976 stocks

Surgical & Medical Instruments Industry

40th out of 99 stocks

3.5

Analyst's Opinion

Consensus Rating
Alpha Tau Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.67, Alpha Tau Medical has a forecasted upside of 322.7% from its current price of $3.47.
Amount of Analyst Coverage
Alpha Tau Medical has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.32% of the float of Alpha Tau Medical has been sold short.
Short Interest Ratio / Days to Cover
Alpha Tau Medical has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Alpha Tau Medical has recently decreased by 22.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Alpha Tau Medical does not currently pay a dividend.
Dividend Growth
Alpha Tau Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DRTS.

4.1

News and Social Media Coverage

News Sentiment
Alpha Tau Medical has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Alpha Tau Medical this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for DRTS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
2 people have added Alpha Tau Medical to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alpha Tau Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 1.47% of the stock of Alpha Tau Medical is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Alpha Tau Medical are expected to decrease in the coming year, from ($0.50) to ($0.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alpha Tau Medical is -10.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alpha Tau Medical is -10.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alpha Tau Medical has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

DRTS Price History

30 days | 90 days | 365 days | Advanced Chart

DRTS Stock News Headlines

September 16, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Alpha Tau Medical's (NASDAQ:DRTS) Cash Burn Situation

September 14, 2023 | stockhouse.com

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center

October 3, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

August 24, 2023 | finance.yahoo.com

Alpha Tau Medical to Participate in September Investor Conferences

August 17, 2023 | finance.yahoo.com

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

August 2, 2023 | finance.yahoo.com

Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023

May 25, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Alpha Tau Medical Ltd (DRTS)

May 24, 2023 | finance.yahoo.com

Alpha Tau Medical to Participate in June Investor Conferences

October 3, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

May 23, 2023 | msn.com

Recap: Alpha Tau Medical Q1 Earnings

May 22, 2023 | finance.yahoo.com

Should You Buy Alpha Tau Medical (DRTS) Ahead of Earnings?

May 18, 2023 | markets.businessinsider.com

Alpha Tau Medical Ltd (DRTS) Receives a Buy from H.C. Wainwright

May 17, 2023 | finance.yahoo.com

Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

May 11, 2023 | finance.yahoo.com

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

May 3, 2023 | finance.yahoo.com

Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day

April 24, 2023 | msn.com

Alpha Tau Medical a new buy at HC Wainwright on proprietary radiation therapy

March 8, 2023 | finance.yahoo.com

Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

March 1, 2023 | finance.yahoo.com

Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases

December 13, 2022 | finance.yahoo.com

Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023

November 23, 2022 | finanznachrichten.de

Alpha Tau Medical Ltd.: Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

November 9, 2022 | finance.yahoo.com

Alpha Tau to Present at Upcoming November Investor Conferences

October 21, 2022 | finance.yahoo.com

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology

September 24, 2022 | seekingalpha.com

DRTS Alpha Tau Medical Ltd.

September 19, 2022 | finance.yahoo.com

Alpha Tau Medical Ltd.'s (NASDAQ:DRTS) largest shareholders are individual investors with 47% ownership, insiders own 26%

September 8, 2022 | finance.yahoo.com

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy

September 1, 2022 | finance.yahoo.com

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

August 30, 2022 | finance.yahoo.com

Alpha Tau Medical to Participate in Upcoming September Investor Conferences

See More Headlines

Receive DRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter.

DRTS Company Calendar

Last Earnings: 8/28/2023
Today: 10/03/2023
Next Earnings (Estimated): 11/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DRTS
CUSIP: N/A
CIK: 1871321
Web: healthcarecapitalcorp.com
Phone: 972-3577-4115
Fax: N/A
Employees: 94
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $14.67
High Stock Price Forecast: $23.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +308.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,760,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -22.64%
Return on Assets: -19.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.74
Quick Ratio: 18.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.58 per share
Price / Book: 2.27

Miscellaneous

Outstanding Shares: 69,370,000
Free Float: 41,971,000
Market Cap: $249.04 million
Optionable: Not Optionable
Beta: 0.93

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Uzi Sofer (Age 53)
CEO & Chairman
Comp: $1.58M

Mr. Raphi Levy (Age 38)
Chief Financial Officer
Comp: $1.24M

Mr. Amnon Gat (Age 48)
Chief Operations Officer
Comp: $497k

Mr. Ronen Segal (Age 50)
Chief Technology Officer
Comp: $380k

Dr. Robert B. Den M.D. (Age 44)
Chief Medical Officer & Member of Scientific Advisory Board
Comp: $565k

Prof. Yona Keisari (Age 76)
Chief Scientific Officer & Member of Scientific Advisory board

Ms. Rebecca Becker
VP of legal

Mr. Peter M. Melnyk (Age 61)
Chief Commercial Officer

Prof. Itzhak Kelson (Age 83)
Chief Physics Officer & Member of Scientific Advisory Board

Ms. Yael Zeiger (Age 40)
Corp. Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

DRTS Stock - Frequently Asked Questions

Should I buy or sell Alpha Tau Medical stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alpha Tau Medical in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRTS shares.
View DRTS analyst ratings or view top-rated stocks.
What is Alpha Tau Medical's stock price forecast for 2023?: 3 analysts have issued 1 year price objectives for Alpha Tau Medical's shares. Their DRTS share price forecasts range from $9.00 to $23.00. On average, they anticipate the company's share price to reach $14.67 in the next twelve months. This suggests a possible upside of 308.5% from the stock's current price.
View analysts price targets for DRTS or view top-rated stocks among Wall Street analysts.
How have DRTS shares performed in 2023?: Alpha Tau Medical's stock was trading at $3.18 at the beginning of 2023. Since then, DRTS stock has increased by 12.9% and is now trading at $3.59.
View the best growth stocks for 2023 here.
Are investors shorting Alpha Tau Medical?: Alpha Tau Medical saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 122,200 shares, a decline of 22.9% from the August 31st total of 158,500 shares. Based on an average daily volume of 70,200 shares, the short-interest ratio is currently 1.7 days. Currently, 0.3% of the company's shares are short sold.
View Alpha Tau Medical's Short Interest.
When is Alpha Tau Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 28th 2023.
View our DRTS earnings forecast.

How were Alpha Tau Medical's earnings last quarter?: Alpha Tau Medical Ltd. (NASDAQ:DRTS) posted its quarterly earnings data on Monday, August, 28th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.13).
What is Alpha Tau Medical's stock symbol?: Alpha Tau Medical trades on the NASDAQ under the ticker symbol "DRTS."
How do I buy shares of Alpha Tau Medical?: Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Alpha Tau Medical's stock price today?: One share of DRTS stock can currently be purchased for approximately $3.59.
How much money does Alpha Tau Medical make?: Alpha Tau Medical (NASDAQ:DRTS) has a market capitalization of $249.04 million. The company earns $-33,760,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.
How can I contact Alpha Tau Medical?: Alpha Tau Medical's mailing address is 301 N. MARKET STREET STE 1414, WILMINGTON DE, 19801. The official website for the company is healthcarecapitalcorp.com. The company can be reached via phone at 972-3577-4115 or via email at ir@alphatau.com.

This page (NASDAQ:DRTS) was last updated on 10/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial